logo
Plus   Neg
Share
Email

Allergan : FDA Oks Juvéderm VOLUMA XC For Mid-Face Injection Via Cannula

Allergan plc (AGN) said that it received U.S. Food and Drug Administration approval for the use of Juvéderm VOLUMA XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE cannula for cheek augmentation to correct age-related volume deficit in the mid-face in adults over 21.

A cannula is a thin, flexible tube with a rounded tip that can serve as an effective delivery system. Use of a cannula allows for injection of Juvéderm VOLUMA XC in the cheek area.

Juvéderm VOLUMA XC was first approved by the FDA in 2013 and is formulated with Allergan's proprietary VYCROSS technology, which blends different molecular weights of hyaluronic acid, contributing to the gel's duration.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Groupe Renault plans to cut about 14,600 jobs across the world and lower its production capacity. The plan includes almost 4,600 jobs reduction in France, through voluntary retirement and retraining. Amazon said it will convert 125,000 of the 175,000 temporary workers it hired in March amid the coronavirus pandemic, to permanent full-time employees in June. The e-commerce giant had hired the temporary employees in March to meet strong consumer demand amid the lockdown. The job openings were in Amazon's fulfillment centers and its delivery network. Mitsubishi Motors North America inc. recalled 141,200 cars and sports utility vehicles (SUVs) due to potential corrosion of the front cross member because of salt water exposure such as from road salt use in cold-weather, according to the National Highway Traffic Safety Administration. The recall is expected to begin on July 14, 2020.
RELATED NEWS
Follow RTT